MassIVE MSV000086990

Partial Public

Label-free proteomics to study the effect of IL-9 on MDA-MB-231 and HeLa cells

Description

To study the proteomic profile of HeLa and MDA-MB-231 upon IL-9 stimulation, we treated both the cell-lines with the cytokine for 24 hours. Quantitative label-free proteomic analysis was then performed and abundance ratios were obtained for proteins from cells in IL-9 treated v. untreated conditions. Method: TRIzol (Thermo Fisher Scientific, USA, Cat. No. 15596026) reagent-based method was used for protein extraction from MDA-MB-231 and HeLa. Cells were washed with PBS and lysed in TRIzol followed by protein precipitation using manufacturers protocol. The extracted protein was re-solubilized in Urea (8 M) Thiourea (2 M) Tris-Cl Buffer. Protein was treated with 15 mM Dithiothreitol (DTT) for 1 hour at 50 deg C followed by 30 mM Iodoacetamide (IAA) treatment and digestion with trypsin (Trypsin Gold, Mass Spectrometry Grade, Promega, USA, Cat. No. V5280). Digested protein was desalted using C18 Stage tips. 500 ng peptides were injected using EasyNLC 1200 (Thermo Fisher Scientific, USA) instrument into a Q-Exactive Plus Orbitrap Mass Spectrometer with a 2-hour gradient in Data Dependent Acquisition (DDA) mode (Resolution: MS1=70000, MS2=17500). Mass Spectra were then analyzed using Proteome Discoverer 2.2 software (ThermoFisher Scientific, USA, Cat. No. XCALI-97808). Mascot and SequestHT were employed as search engines for discovery proteomics. For label-free quantification, standard workflows by the manufacturer were employed with the following specific parameters: the samples were normalized with respect to the peak-area based total peptide amount, the permitted retention time shift (RT) was set to 2 min, precursor mass tolerance to 2 ppm, fragment mass tolerance to 0.02 Da and the false discovery rate (FDR) to 0.01 (strict). Only unique peptides were included for peak-area based quantification of proteins. For statistical analysis of identified proteins, hypothesis testing was performed using background-based ANOVA. Proteins identified were filtered for high FDR confidence and only proteins with 2 or more unique peptides were considered for relative quantification and abundance ratios were calculated. Differentially expressed proteins (with at least 1.5 fold upregulation or downregulation) thus obtained were used for pathway enrichment and functional annotation analysis using DAVID bioinformatics tool, PANTHER and STRING database. Heatmaps were rendered using ClustVis Heatmap online server. [doi:10.25345/C52V3W] [dataset license: CC0 1.0 Universal (CC0 1.0)]

Keywords: IL-9 ; breast cancer ; cervical cancer ; metastasis ; actin remodeling ; actomyosin ; interleukin

Contact

Principal Investigators:
(in alphabetical order)
Rahul Purwar, IIT Bombay, India
Submitting User: soumitram

Publications

Das S, Surve V, Marathe S, Wad S, Karulkar A, Srinivasan S, Dwivedi A, Barthel SR, Purwar R.
IL-9 Abrogates the Metastatic Potential of Breast Cancer by Controlling Extracellular Matrix Remodeling and Cellular Contractility.
J Immunol. 2021 Jun 1;206(11):2740-2752. Epub 2021 May 21.

Number of Files:
Total Size:
Spectra:
Subscribers:
 
Owner Reanalyses
Experimental Design
    Conditions:
    Biological Replicates:
    Technical Replicates:
 
Identification Results
    Proteins (Human, Remapped):
    Proteins (Reported):
    Peptides:
    Variant Peptides:
    PSMs:
 
Quantification Results
    Differential Proteins:
    Quantified Proteins:
 
Browse Dataset Files
 
FTP Download Link (click to copy):

- Dataset Reanalyses


+ Dataset History


Click here to queue conversion of this dataset's submitted spectrum files to open formats (e.g. mzML). This process may take some time.

When complete, the converted files will be available in the "ccms_peak" subdirectory of the dataset's FTP space (accessible via the "FTP Download" link to the right).
Number of distinct conditions across all analyses (original submission and reanalyses) associated with this dataset.

Distinct condition labels are counted across all files submitted in the "Metadata" category having a "Condition" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct biological replicates across all analyses (original submission and reanalyses) associated with this dataset.

Distinct replicate labels are counted across all files submitted in the "Metadata" category having a "BioReplicate" or "Replicate" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct technical replicates across all analyses (original submission and reanalyses) associated with this dataset.

The technical replicate count is defined as the maximum number of times any one distinct combination of condition and biological replicate was analyzed across all files submitted in the "Metadata" category. In the case of fractionated experiments, only the first fraction is considered.

"N/A" means no results of this type were submitted.
Originally identified proteins that were automatically remapped by MassIVE to proteins in the SwissProt human reference database.

"N/A" means no results of this type were submitted.
Number of distinct protein accessions reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct unmodified peptide sequences reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct peptide sequences (including modified variants or peptidoforms) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Total number of peptide-spectrum matches (i.e. spectrum identifications) reported across all analyses (original submission and reanalyses) associated with this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins quantified across all analyses (original submission and reanalyses) associated with this dataset.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
Number of distinct proteins found to be differentially abundant in at least one comparison across all analyses (original submission and reanalyses) associated with this dataset.

A protein is differentially abundant if its change in abundance across conditions is found to be statistically significant with an adjusted p-value <= 0.05 and lists no issues associated with statistical tests for differential abundance.

Distinct protein accessions are counted across all files submitted in the "Statistical Analysis of Quantified Analytes" category having a "Protein" column in this dataset.

"N/A" means no results of this type were submitted.
This dataset may not contain all raw spectra data as originally deposited in PRIDE. It has been imported to MassIVE for reanalysis purposes, so its spectra data here may consist solely of processed peak lists suitable for reanalysis with most software.